Azithromycin alters spatial and temporal dynamics of airway microbiota in idiopathic pulmonary fibrosis.

ABSTRACT:

Background

High bacterial burden in the lung microbiota predicts progression of idiopathic pulmonary fibrosis (IPF). Azithromycin (AZT) is a macrolide antibiotic known to alter the lung microbiota in several chronic pulmonary diseases, and observational studies have shown a positive effect of AZT on mortality and hospitalisation rate in IPF. However, the effect of AZT on the lung microbiota in IPF remains unknown.

Methods

We sought to determine the impact of a 3-month course of AZT on the lung microbiota in IPF. We assessed sputum and oropharyngeal swab specimens from 24 adults with IPF included in a randomised controlled crossover trial of oral AZT 500 mg 3 times per week. 16S rRNA gene amplicon sequencing and quantitative PCR (qPCR) were performed to assess bacterial commu

SUBMITTER: Gijs PJ 

PROVIDER: S-EPMC10204823 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature